Uterine Cervical Neoplasms
📧 Sign up to get email alerts when something new happens for Uterine Cervical Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2019-03-07EMA Withdrawn: Topotecan Actavis (topotecan) — Actavis Group PTC ehf
EMA withdrawn topotecan (Topotecan Actavis) indicated for uterine cervical neoplasms and small cell lung carcinoma; product withdrawn by MAH…
-
EMA withdrawal · 2018-07-27EMA Application withdrawn: Raligize — FGK Representative Service GmbH
The EMA withdrew the application for Raligize (FGK Representative Service GmbH) with a stated therapeutic area of uterine cervical neoplasms…
-
EMA withdrawal · 2018-07-13EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.
Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and …